Wolman Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Wolman disease, an intense manifestation of lysosomal acid lipase deficiency, is characterized by swift and extensive accumulation of lipids in organs and tissues. It manifests with notable symptoms during the neonatal or infantile phase, including significant hepatosplenomegaly, liver failure, steatorrhea-associated diarrhea, and vomiting. Although the disease can also emerge prenatally with indications like hepatomegaly, ascites, and calcified adrenal glands, its more common onset occurs within the initial weeks of life. This phase is marked by abdominal distension, substantial hepatosplenomegaly (which can even manifest in the neonatal period), and intermittent ascites. A notable radiographic sign is the presence of calcified adrenal glands. Children affected by this condition experience notable gastrointestinal disturbances, such as vomiting and diarrhea accompanied by steatorrhea. These symptoms can result in abrupt cessation of weight gain and gradual deterioration of psychomotor functions without specific neurological indicators. Subsequently, severe anemia and cachexia become evident. The underlying enzymatic deficiency stems from severe mutations in the acid lipase gene (LIPA or LAL) located at 10q24-q25. Swift confirmation of the diagnosis can be achieved by assessing enzymatic activity in leukocytes or dried blood spots, which reveals a near-complete deficiency. The differential diagnosis encompasses conditions like familial hemophagocytic histiocytosis, various phagocytic syndromes, Gaucher disease type II, Niemann-Pick disease type A, and malignancies like leukemia or neuroblastoma. In regions such as the United States and the European Union, enzyme replacement therapy utilizing sebelipase lipase is accessible and has demonstrated the ability to extend survival rates. Additionally, there have been instances where very early bone marrow or cord blood transplants have been employed, yielding some benefits in a limited number of cases.
Thelansis’s “Wolman Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wolman Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Wolman Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Wolman Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment